Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial

Study limitation reported by the research below: “The trial is phase 1b/2, single-arm, so efficacy comparisons to standard of care cannot be made directly from this study.”